GLPBio

Dehydrodiisoeugenol

Catalog No.: GC38184Purity:>98.00%
Dehydrodiisoeugenol (DEH) is a representative and major benzofuran-type neolignan found in Myristica fragrans Houtt, possessing antibacterial, anti-inflammatory, anticancer, and antioxidant properties.

Die Produkte sind ausschließlich für Forschungszwecke bestimmt. Nicht zur Anwendung am Menschen. Wir verkaufen nicht an Patienten.


Dehydrodiisoeugenol
Cas No.: 2680-81-1
10mM (in 1mL DMSO)In Stock
$70.00
1
1mgIn Stock
$24.00
1
5mgIn Stock
$64.00
1
10mgIn Stock
$112.00
1
20mgIn Stock
$184.00
1

Zitate (Citations)

1 publicationsPublikationen von Forschern, die dieses Produkt verwenden

Beschreibung (Description)

Dehydrodiisoeugenol (DEH) is a representative and major benzofuran-type neolignan found in Myristica fragrans Houtt, possessing antibacterial, anti-inflammatory, anticancer, and antioxidant properties. Dehydrodiisoeugenol inhibits the proliferation of colorectal cancer cells and induces apoptosis, autophagy, endoplasmic reticulum stress and cell cycle arrest. Dehydrodiisoeugenol is commonly used in the research related to colorectal cancer, inflammatory diseases and ulcerative colitis[1][2][3].

In vitro, treatment with Dehydrodiisoeugenol (2.5, 5 and 10µM) for 24h inhibited the activation of the NF-κB and MAPK signaling pathways and dose-dependently suppressed the expression of inflammatory mediators, including NO, iNOS, COX-2, PGE₂, IL-1β, IL-6, and TNF-α in the LPS/IFNγ-induced RAW264.7 ulcerative colitis (UC) model[1]. Treatment with Dehydrodiisoeugenol (40, 80, and 100µM) for 24h significantly inhibited the viability of HCT116 and HT29 cells[1]. Treatment with Dehydrodiisoeugenol at 40µM for 24h induced apoptosis in HCT116 cells, suppressing Bcl-2 expression while upregulating Bax expression[1].

In vivo, oral administration of Dehydrodiisoeugenol at 40mg/kg for 20 days significantly inhibited tumor growth in BALB/c nude mice transplanted with HCT116 cells[1]. Oral gavage administration of Dehydrodiisoeugenol at 20mg/kg/d for 8 days significantly improved rectal bleeding in DSS-induced mice[1].

References:
[1] Yi F, Chen N, Zhao M, et al. Dehydrodiisoeugenol targets NOD2 exerting dual effects against colitis and colorectal cancer: a double-edged sword. Mol Med. 2025;31(1):221.
[2] Li C, Zhang K, Pan G, et al. Dehydrodiisoeugenol inhibits colorectal cancer growth by endoplasmic reticulum stress-induced autophagic pathways. J Exp Clin Cancer Res. 2021;40(1):125.
[3] Murakami Y, Shoji M, Hirata A, Tanaka S, Yokoe I, Fujisawa S. Dehydrodiisoeugenol, an isoeugenol dimer, inhibits lipopolysaccharide-stimulated nuclear factor kappa B activation and cyclooxygenase-2 expression in macrophages. Arch Biochem Biophys. 2005;434(2):326-332.

Protokoll (Protocol)

Cell experiment [1]:

Cell lines

RAW264.7

Preparation Method

RAW 264.7 cells were seeded overnight in a 96-well plate, and treated with the positive control drug (curcumin, 5µM) and Dehydrodiisoeugenol (2.5, 5, 10µM), following stimulated by LPS (0.5µg/ml) and recombinant IFNγ (10ng/ml) for 24h, determining the concentration of various inflammatory factors in cell culture supernatant.

Reaction Conditions

2.5, 5, 10µM; 24h

Applications

Dehydrodiisoeugenol could inhibit the production of NO, iNOS, COX2, PGE2, IL-1β, IL-6, and TNFα in LPS/IFNγ-stimulated RAW264.7 cells in a dose-dependent manner.
Animal experiment [1]:

Animal models

BALB/c nude mice transplanted with HCT116 cells

Preparation Method

BALB/c nude mice were subcutaneously injected with HCT116 cells into their bodies. About one week later, the successfully transplanted mice were randomly divided into the control group and the Dehydrodiisoeugenol (DEH) group. Then, the control group received intraperitoneal injection of 100µL PBS (containing 0.1% DMSO), while the mice in the DEH group were orally gavaged with DEH at 40mg/kg once daily for 20 consecutive days. Tumor sizes and body weights were measured and recorded every 5 days. The mice were euthanized, and tumors were excised, photographed, and weighed.

Dosage form

40mg/kg; 20d; p.o.

Applications

There was no significant difference in average weight between the two groups of mice. However, tumor weight and volume were significantly smaller in the DEH (40mg/kg) treated group compared to the control group.

References:
[1]Yi F, Chen N, Zhao M, et al. Dehydrodiisoeugenol targets NOD2 exerting dual effects against colitis and colorectal cancer: a double-edged sword. Mol Med. 2025;31(1):221.

Produktdokumente (Product Documents)

Purity:>98.00%Appearance:A solid

Chemische Eigenschaften (Chemical Properties)

CAS-Nr.
2680-81-1
SMILES
OC1=CC=C(C2OC3=C(OC)C=C(/C=C/C)C=C3C2C)C=C1OC
Summenformel
C20H22O4
Molekulargewicht
326.39
Löslichkeit
DMSO: ≥ 250 mg/mL (765.95 mM)
Lagerung
Store at -20°C
Allgemeine Hinweise
Wählen Sie anhand der Löslichkeitsdaten des Produkts ein geeignetes Lösungsmittel. Aliquotieren Sie die Stammlösung nach der Herstellung, um wiederholte Gefrier-Auftau-Zyklen zu vermeiden.
Verwenden Sie Stammlösungen bei Lagerung bei -80°C innerhalb von 6 Monaten bzw. bei -20°C innerhalb von 1 Monat.
Zur Verbesserung der Löslichkeit das Röhrchen auf 37°C erwärmen und für eine angemessene Dauer beschallen.
Versandbedingungen
Evaluierungsmuster werden mit Kühlakkus versandt. Andere verfügbare Größen werden bei Raumtemperatur oder auf Anfrage mit Kühlakkus versandt.

Rechner (Calculators)Molarität / Verdünnung / Molekulargewicht / Einheitenumrechnung / In-vivo-Formulierung / Löslichkeit

g/mol

Reviews

Review for Dehydrodiisoeugenol

Rating: 5
  • 5 Star100%
  • 4 Star0%
  • 3 Star0%
  • 2 Star0%
  • 1 Star0%